Aim: Statins reduce morbidity and mortality among patients with diabetes, but their use remains suboptimal. Understanding trends in statin use may inform strategies for improvement. Methods: We enrolled a national, retrospective cohort of 899,664 veterans aged ≥ 40 years with diabetes in 2003. We followed them through 2011, dividing the nine-year follow-up into 90-day periods. For each period, we determined statin use, defined as possession of ≥30-day supply. We examine factors associated with statin uptake among baseline non-users with a multivariate model. Results: Baseline prevalence of statin use was 43%, increased by 1.8% per period (p for trend b 0.001), and reached a maximum of~59%. Statin use among non-Hispanic racial/ethnic minorities lagged behind their white counterparts. Among baseline non-users, statin use was 9% after Year 1 and reached 36% by Year 9. Factors associated with statin uptake included use of hypoglycemic agents, HbA1c between 7 and 8.9% (53-74 mmol/mol), hypertension, heart failure, peripheral vascular disease, and Hispanic ethnicity. Conclusion: Statin use is slowly increasing among patients with diabetes, and at varying rates within subgroups of this population. Policies that prioritize these subgroups for statin promotion may help guide future, intervention-based research to increase compliance with current guidelines.
Introduction
Patients with diabetes have a well-established elevated risk of cardiovascular disease. Statins reduce the risk of all-cause mortality, cardiovascular mortality, stroke, and myocardial infarction for patients with diabetes. [1] [2] [3] Statins may also reduce the risk of diabetic complications, such as foot ulcers and amputations. [4] [5] [6] Benefits of statins are not restricted to patients with marked hyperlipidemia or known cardiovascular disease. 7 Recommendations regarding statin use have been relatively constant for patients with diabetes over the past 15 years. The Adult Treatment Panel (ATP) III guideline published in 2002 recommend statins for patients with diabetes and an additional risk factor: hypertension, older age (≥45 years for men and ≥55 year for women), a family history of cardiovascular disease, or active tobacco use. 8 Given the prevalence of these risk factors, the vast majority of patients with diabetes would have qualified for statin use while ATP III guidelines were in effect even if low density lipoprotein cholesterol (LDL-c) levels were not elevated. 9 Recommendations recently sim-Despite consistent core of recommendations since 2002, b60% of the current population of patients with diabetes is taking a statin. 11, 12 While these cross-sectional estimates are informative, the adoption of statins has likely been dynamic, changing over time and in different subgroups. Understanding the real-world trends in statin use in a national cohort may help inform initiatives to optimize statin use for patients with diabetes and increase compliance with guideline recommendations.
In this paper, we describe longitudinal trends in statin use within a national cohort of patients with diabetes while the ATP III guidelines were in effect (2003−2011) . We also investigated clinical factors and patient demographics associated with statin use among baseline non-users.
Methods

Study design and data sources
This is a national, retrospective cohort study of all patients with diabetes who were at least 40 years old and treated in the U.S. Department of Veterans Affairs (VA) healthcare system during 2003. VA and Medicare data was used to identify patients with diabetes based on whether 1) they received at least one prescription for a diabetes medication in 2003, or 2) two or more International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 250.xx for diabetes were present in any in-patient or outpatient visits in 2001-2002. 13 Patients were followed from 2003 until death or December 31, 2011 (study completion). Therefore, the entire study took place prior to the 2013 ACC/AHA guidelines and while ATP III was in effect. The cohort was constructed using de-identified data from the VA National Patient Care Database, the VA Decision Support System Pharmacy Datasets, and the Centers for Medicare and Medicaid Services Medicare claims files, including Part D Event files. The Edward Hines, Jr. Veterans Affairs Hospital IRB approved this study.
Outcome
Our primary outcome was the prevalence of statin use over time, among the entire cohort. Statin use was defined as receipt of at least a 30-day supply during a 90-day period. This definition provided a lenient estimate of statin use because 1) possessing a medication does not necessarily indicate taking it, and 2) one pill every three days is a modest criterion for use. The definition was purposefully constructed this way so that estimates of suboptimal use were conservative. The nine-year study was divided into 90-day periods, with the baseline period defined as January 1, 2003 through March 30, 2003 . If a patient filled a prescription at the end of a 90-day period, the remaining days' supply was rolled over to the next period. As secondary analyses, we also examined statin use over time among: 1) patients not receiving cholesterol lowering medications in the baseline period, and 2) patients with comorbid cardiovascular disease, defined as myocardial infarction, heart failure, stroke, or peripheral arterial disease diagnosed prior to or during the study. These two are not mutually exclusive subgroups; a patient could be included in neither, one, or both of these subgroup analyses.
Explanatory variables
The following variables were assessed at baseline and modeled as time-independent: age at study start date, sex, race/ethnicity, marital status, and whether diabetes was diagnosed more than five years prior to the study start date. Co-existing conditions, HbA1c, body mass index (BMI), LDL-c, diabetes medication use, and use of nonstatin cholesterol lowering medication were all assessed at baseline and for each period as time-varying covariates. All records for fiscal year 2002 were used to obtain values for the baseline period. If individuals had multiple measurements of HbA1c, body mass index (BMI), and LDL-c taken within the baseline period or during a follow-up period, we calculated an average value across time points within the same period. When there were no measures of an independent variable during a follow-up period, we used the last observation carried forward (LOCF) method to impute the value for the current period. Missing values for the baseline period were not imputed. Persons whose values were not measured or missing at baseline for any other reason were classified as unknown. Of the 25 million person-periods, 49% of A1c values and 52% of LDL-c were imputed with the LOCF method, while 19% of A1c values and 22% of LDLc were classified as missing.
Comorbidities were identified using the Elixhauser algorithm for the baseline period using all records from the past one year and for each follow-up period.
14 The subset of patients with cardiovascular disease was identified using this algorithm's definitions for heart failure, stroke, and peripheral vascular disease, with the addition of myocardial infarction, which was identified by ICD-9 code 410. Antidiabetic medications were also identified at baseline and during each follow-up period. Possession of 30-day supply or more of insulin and oral agents during the last year before the baseline or during each follow-up period was used to identify whether a patient used insulin, or oral agents, or both. Similar to our definition of statin use, use of non-statin cholesterol-lowering medications was identified for each period separately. A patient who filled a non-statin cholesterollowering medication for 30 days or longer during a period was defined as a user of non-statin cholesterol medications. Non-statin cholesterol-lowering medications included fibrates, bile acid sequestrants, niacin, or ezetimibe.
Statistical analysis
Descriptive statistics were computed for the entire cohort, the subset of the sample not receiving cholesterol-lowering medications during the baseline period, and the subset with cardiovascular disease. Statin use for the overall cohort as well as the two subgroups were identified for each of the 36 follow-up periods and plotted for trends over time. Patients taking a statin may be more likely to survive, such that an increase in the proportion of the cohort taking a statin over time may reflect the death of patients not on a statin, rather than initiation or re-introduction of this drug class (survival bias). To assess for this potential bias, we also analyzed the trend in statin use among patients surviving to the end of the nine-year study.
We examined factors affecting statin initiation among patients not receiving cholesterol-lowering medications during the baseline period in multivariable analyses. Statin use was modeled as timevarying to best reflect the complicated nature of discontinuations and/or switches to other classes of cholesterol-lowering medications. Each patient can potentially be represented in our data for up to 36 periods. To account for the repeated nature of our data and correct for clustering in estimating standard errors, we modeled statin use as a function of the explanatory variables using a two-level, random-intercept logistic regression. Stata SE v14 was used for all statistical analysis (StataCorp, College Station, TX).
Results
The total cohort consisted of 899,664 patients with diabetes aged 40 years or older who were treated in the VA healthcare system. Of those, 480,111 (53.4%) did not receive any cholesterol-lowering medications during the baseline period and 516,407 (57.4%) did not receive a statin. The majority (89.1%) of patients on a cholesterollowering medication with a cholesterol measurement at baseline had an LDL-c at or under the ATP III goal of 130 mg/dL. Of the total cohort,494,274 (54.9%) had baseline comorbid cardiovascular disease; and 520,726 (57.9% of the total cohort) survived to the end of the nine-year study. The average length of follow-up was 28 ± 11 periods (82 ± 34 months).
The total cohort was predominantly male (98%), with 57% at least 65 years old and 77% non-Hispanic white (Table 1) . Eighteen percent had diabetes for five years or longer prior to the study start date. The majority (82%) were not taking insulin. The proportion of the total cohort with HbA1c b 7% (53 mmol/mol) was 35.4%; 27.3% had HbA1c values between 7 and 8.9% (53-74 mmol/mol).
Longitudinal trends in statin use
Statin use among the total cohort increased from 42.6% at baseline to 59.2% toward the end of the nine-year follow-up period (Fig. 1) . Patients were 1.8% more likely to use statins in each succeeding 90-day period (unadjusted p-value for trend b 0.001). Our sensitivity analysis, which restricted the cohort to those who survived the entire study period to account for survival bias, demonstrated a similar trend to the total cohort. Statin use among the surviving cohort increased from 44% to 60%. Among those with cardiovascular disease at baseline, statin use increased from 43% to 58%. Among those not taking a cholesterol-lowering medication during the baseline period, the shift toward statin use was slow. After the first year (at the conclusion of period 4), 15% were taking a statin. This proportion reached 46% toward the end of the nine-year study.
Statin use increased for patients of all races and ethnicities, although the amount of improvement differed (Fig. 2) . Use among Hispanic patients increased the most (36% to 61%), reaching parity with non-Hispanic white patients toward the end of the study. Use among non-Hispanic black patients started out considerably lower than that for non-Hispanic white patients (32% vs 46%) and reached a high of 54%. In contrast, patients in the Other group (non-Hispanic, nonblack minorities, or those whose race/ethnicity is unknown) started with the lowest statin use and experienced the slowest gains in uptake (26% to 38%). 
Factors associated with statin uptake among patients not taking cholesterol lowering medications at baseline
Among patients who were not taking a cholesterol-lowering medication during the baseline period, clinically overt diabetes-i.e. necessitating hypoglycemic agents or evidenced by elevated HbA1c levels-was associated with increased odds of statin uptake. Specifically, as the intensity of diabetic medication regimens increased from diet-control to oral hypoglycemic agents, and the introduction of insulin, the odds of statin use increased. Compared to patients who were not taking any hypoglycemic medications, patients taking both oral agents and insulin experienced a 19-fold increase in the likelihood of starting a statin (p b 0.001, Table 2 ). Compared to patients with HbA1c levels below 7% (53 mmol/mol), those with HbA1c values between 7% and 8.9% (53-74 mmol/mol) were 10% more likely (Adjusted Odds Ratios [AOR] = 1.10; 95% CI, 1.09-1.10) to start a statin, whereas those with unmeasured HbA1c were less likely to start a statin (AOR = 0.47; 95% CI, 0.47-0.48; p b 0.001). After adjustment, patients diagnosed with diabetes more than five years prior to the baseline were less likely to initiate a statin (AOR = 0.61; 95% CI, 0.59-0.63; p b 0.001). Comorbid cardiovascular disease was associated with increased odds of statin uptake. Specifically, AORs for those with hypertension, chronic heart failure, or peripheral vascular disorders were 2.78 (95% CI, 2.73-2.79), 1.09 (95% CI, 1.08-1.10), and 1.18 (95% CI, 1.17-1.19), respectively (all p-values b 0.001, Table 2 ).
Hispanic patients were most likely to be started on a statin (AOR 1.11; 95% CI, 1.07-1.16; p b 0.001, Table 2 ). Compared to nonHispanic white patients, non-Hispanic black patients were 26% less likely (AOR = 0.74; 95% CI, 0.72-0.76; p b 0.001) to be started on a statin, and patients in the Other group were 56% less likely (AOR = 0.62; 95% CI, 0.58-0.66; p b 0.001).
Discussion
Statin use in the 2003 cohort of VA patients with diabetes aged 40 years or older increased from~43% to just under 60% during the nine-year follow-up period. This increase most likely reflected statin initiation rather than survival bias. Our proportions at the end of the study date are similar to that reported for the general U.S. population. According to 2011-2012 National Health and Nutrition Examination Survey (NHANES) data, an estimated 58.8% of Americans with diabetes between the ages of 40 and 75 years are taking a statin. 11 An estimated 5 to 15% of patients do not tolerate statins. 15, 16 Another 10 to 15% of patients experience no substantial reduction in their LDLcholesterol, although this is not a clear indication to stop therapy because patients with diabetes may still experience cardio-protective benefits. 1, 17 Assuming between 5 and 30% of our cohort was not taking a statin due to intolerance or limited effect on their LDLcholesterol levels, this leaves 10 to 35% of the cohort (or between 89,966 and 314,882 patients) who were not receiving a statin despite their elevated cardiovascular risk. Diabetes has been recognized as a coronary heart disease (CHD) risk equivalent since 2002. 8 However, our study suggests that not all diagnoses of diabetes are given equal weight when considering statin use. Patients with HbA1c values N 7% (53 mmol/mol) or who were treated with hypoglycemic medications were more likely to receive a statin. Co-existing cardiovascular disease was also associated with an increased likelihood of statin use. This association has been demonstrated previously in a large U.S. and Canadian surveys, as well as in a U.S. managed care system. 11, 18, 19 The findings that more clinically apparent diabetes and cardiovascular disease may trigger statin initiation suggest that clinicians may prioritize statin use among patients with suboptimal control of diabetes and other cardiovascular domains. This potential correlation between statin use and poorly controlled diabetes and/or cardiovascular disease was not detected in an earlier study within the VA healthcare system. 20 One potential explanation for this emerging pattern is that diabetes was not widely perceived as a CHD risk equivalent at the time of the Jackson et al. study, but it has subsequently gained recognition as such. Recent data identify cardiovascular disease and diabetes as concordant comorbidities that now share similar clinical management strategies and goals. 21, 22 This increases the odds of achieving shared goals, including LDL-cholesterol level targets. 23 Our study findings extend these results by suggesting that diabetes with HbA1c values N 7, compared to more mild disease, is a stronger clinical trigger for achieving goals shared with cardiovascular disease. Our study also tracks patterns in racial and ethnic disparities regarding statin use for patients with diabetes in an equal-access healthcare system. Prior VA studies have demonstrated that black and Hispanic patients with diabetes are less likely to receive LDL-c testing or attain LDL-c level goals than their white counterparts. 24, 25 A decade later, our study documents the persistence of healthcare disparities for management of hyperlipidemia among black patients with diabetes. It is somewhat encouraging that the gap in statin uptake closed during the study period for Hispanic patients. Understanding how this was achieved may provide useful insights into addressing remaining disparities and preserving gains toward equity in the VA system.
Our study raises an important policy issue: should efforts to promote statin use focus on subgroups with low statin use but also relatively low cardiovascular risk (i.e. patients with diet-controlled diabetes and no cardiovascular comorbidities), or should they focus on groups with higher statin use but also higher cardiovascular risk (i.e. patients with diabetes and a prior myocardial infarct). If a healthcare goal is to ensure all patients with diabetes receive statins, and increase compliance with current guidelines, protocol-driven health service interventions may be needed to overcome current difference based on diabetes severity, additional cardiovascular risks, and race/ethnicity. Such protocols have successfully increased statin use for patients with diabetes in different healthcare systems. 26, 27 Healthcare system interventions aimed at improving diabetes management have the potential to decrease racial and ethnic disparities, regardless of whether or not they specifically focus on improving care for minority patients. 28, 29 While protocol-driven initiatives may be beneficial in increasing the use of statins, we recognize that clinical discretion is still required to determine appropriate deviations. For instance, physicians tend not to prescribe statins for patients with a short life expectancy. 30 Increasing age and comorbid cancer were associated with lower odds of statin prescription in our cohort, which may be entirely appropriate. The strengths of this study include its large sample size, longitudinal data, the availability of laboratory values and medication use, and use of merged information from the VA and Medicare systems. Nevertheless, the study does have limitations. We were unable to control for smoking, an important cardiovascular risk factor. The subgroup of patients we classified as having cardiovascular disease excluded those with coronary artery disease but without ischemic cardiac injury. While this definition is highly specific, it is likely to have misclassified patients with milder cardiovascular disease and resulted in an underestimate of statin use among those with cardiovascular disease and diabetes. We also did not query clinicians to understand the reasoning behind our observed practice patterns. The main limitation of our study may be that the entire study period took place when the ATP III guidelines were in effect. 8 While this avoids the need to account for historical trends in guideline recommendations, it introduces concern that our findings may no longer be generalizable to current practice patterns under the 2013 ACC/AHA guidelines. 10 ATP III guidelines recommended statin use for adult patients with diabetes whose LDL cholesterol level was N 130 mg/dL; it suggested considering statin use for patients with LDL cholesterol levels between 100 and 130 mg/dL. The 2013 ACC/AHA guidelines recommend statin use for all adults with diabetes, regardless of LDL cholesterol levels, with the exception that the level should not drop below 40 mg/dL. 10 We believe our findings remain generalizable to contemporary practice under the ACC/AHA guidelines for the following reasons. 1 Higher LDL cholesterol levels were associated with lower statin use in our population. If providers were refraining from prescribing statins for diabetic patients because their cholesterol levels were below ATP III guideline thresholds, we would have expected to observe the opposite trend. 2 We controlled for LDL levels when assessing the impact of diabetic variables and cardiovascular disease on statin use. LDL-independent estimates should remain germane to clinical practice patterns since statin use is now recommended regardless of LDL levels. 3 Although ATP III guidelines did impose LDL targets, they also recommended statin use for patients with two or more cardiovascular risk factors. Since most patients with diabetes have additional cardiovascular risk factors, both ATP III and ACC/ AHA guidelines are fairly well aligned. 
Conclusion
This study found that HbA1c values N 7 and comorbid cardiovascular disease were associated with increased odds of statin use among a national cohort of VA patients with diabetes. While Hispanic patients achieved parity with their white counterparts, disparities among other minorities persist. Future studies should focus on understanding why these patterns exist to help optimize statin use moving forward. Protocol-driven health systems interventions may be useful in minimizing these differences, but clinicians must retain the ability to deviate from them when clinically appropriate. Resources are limited. To best focus future interventions that improve compliance with ADA guidelines on statin use, we pose the following question: should we target the relatively low-risk group of patients with diabetes, where the number of patients not on a statin is the greatest, but the individual risk-reduction may be the least? Alternatively, should we aim to increase statin use among the higher-risk group of patients, where the number of patients who could benefit may be smaller, but the individual risk-reduction would be greater?
